{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T09:25:11Z","timestamp":1787217911091,"version":"build-2736575974"},"reference-count":8,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.07.001","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:35:02Z","timestamp":1783751702000},"page":"338-340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Best in Class? The Comparative Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists in Preventing Incident CKD Stage 3 or Higher"],"prefix":"10.1053","volume":"88","author":[{"given":"Allison C.","family":"Reaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Sarnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.ajkd.2026.07.001_bib1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/j.ajkd.2026.04.007","article-title":"Comparison of specific glucagon-like peptide-1 receptor agonists on kidney outcomes among patients with type 2 diabetes","volume":"88","author":"Neumiller","year":"2026","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2026.07.001_bib2","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ndt\/gfaf252","article-title":"The kidney failure risk equation in people with CKD and multimorbidity: the effect of competing mortality risks","volume":"41","author":"Walker","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2026.07.001_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-025-01352-5","article-title":"Obesity in cardiorenal syndrome: management opportunities and challenges","volume":"28","author":"Reaves","year":"2025","journal-title":"Curr Hypertens Rep"},{"key":"10.1053\/j.ajkd.2026.07.001_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112910","article-title":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial","volume":"229","author":"Sklepinski","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"20","key":"10.1053\/j.ajkd.2026.07.001_bib5","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.2025.15841","article-title":"Medicare Part D coverage and costs for glucagon-like peptide-1 receptor agonists","volume":"334","author":"Klebanoff","year":"2025","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2026.07.001_bib6","author":"Freed"},{"key":"10.1053\/j.ajkd.2026.07.001_bib7","author":"Cubanski"},{"key":"10.1053\/j.ajkd.2026.07.001_bib8","author":"Montero"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626009935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:41:41Z","timestamp":1787215301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626009935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":8,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272638626009935"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.07.001","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Best in Class? The Comparative Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists in Preventing Incident CKD Stage 3 or Higher","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.04.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}